BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase)

This analysis identified BUB1, DLGAP5, and ASPM as key genes specifically expressed in HPV-16/18-related cervical cancer, suggesting their potential as biomarkers for prognosis and disease progression.

Furthermore, combined pharmacological inhibition of FOXM1 (FDI-6, RCM-1, thiostrepton) and BUB1 (BAY-1816032) synergistically inhibited the proliferation of HCC cells and xenograft tumors. These findings establish FOXM1-mediated BUB1 upregulation as a key driver of HCC malignancy. Targeting the FOXM1/BUB1 axis represents a promising therapeutic strategy for the treatment of advanced and metastatic HCC, offering new opportunities for HCC therapy.

This sensing of BUB1-regulated expression of the extracellular (dsRNA) and the stromal remodelling mediated by IGFL2 can be considered a pathogenic interface between DDR activation and the inflammatory response of the maladaptive immune response. These revelations ensure that BUB1 and IGFL2 are core immunoregulatory nodes upon which therapeutic actions are understood in accurate oncology, immunotherapy, and the control of autoimmune diseases.

Consistent with this mechanism, aberrant HORMAD1 expression causes sensitivity to MPS1, Aurora B or BUB1 inhibitors currently being investigated as cancer treatments. Our data suggests how out-of-context expression of a meiotic gene imparts genomic instability upon tumour cells and also identifies several associated dependencies as mechanism-based therapeutic targets for a large, biomarker-defined, subset of cancers.

In vivo, xenograft models further validated that BUB1 silencing significantly reduces tumor volume, accompanied by modulation of ferroptosis-related genes in tumor tissues. Collectively, our findings identify BUB1 as a novel prognostic biomarker and therapeutic target for LUAD, revealing a new regulatory mechanism by which BUB1 promotes LUAD progression through the activation of the STAT3/GPX4 axis to suppress ferroptosis.

Molecular docking identified three potential BUB1-targeting drugs (quercetin, cryptolepine, etoposide) with stable binding conformations. Collectively, our fingdings established BUB1 as a diagnostic biomarker for lung cancer, an independent prognostic indicator for LUAD, and a promising therapeutic target, with its inhibition potentially overcoming CSCs-driven treatment resistance.

This study identified six telomere-related genes with high expression and strong diagnostic value in ccRCC, highlighting their association with immune infiltration and potential as diagnostic and therapeutic targets.

This study revealed the important role of BUB1, one of the potential targets of 5-FU, in the development of esophageal cancer. Through bioinformatics analysis and experimental validation, we found that the high expression of BUB1 in esophageal cancer tissues was closely related to the biological properties of the tumor. the regulation of cell cycle by BUB1 and its role in the invasion and migration ability of the cells marked its potential as a new target for the treatment of esophageal cancer.

The identified miRNAs exhibit strong regulatory interactions with these hub genes, while serine/threonine protein kinases emerged as the most significantly associated group. Together, these findings highlight promising biomarker candidates and potential therapeutic targets for gynecological cancers.

BUB1 promotes the proliferation, migration, and invasion of esophageal cancer cells. Increased BUB1 expression is closely associated with tumor differentiation, lymph node metastasis, and clinical stage.

The results of the receiver operating characteristic (ROC) curve, area under the ROC curve, calibration plot, net reclassification index, integrated discrimination improvement index, and decision curve analysis revealed that the model had good discriminating ability, predictive ability, and clinical utility. In conclusion, AURKA, BUB1, and CDK1 are potential prognostic biomarkers of NPC, and a prediction model incorporating the expression levels of AURKA and BUB1 has good discriminating ability, predictive ability, and clinical utility.